A Real-World Multicenter Retrospective Observational Study on Polish Experience with Nintedanib Therapy in Patients with Idiopathic Pulmonary Fibrosis: The PolExNIB Study

Nintedanib is a disease-modifying agent licensed for the treatment of IPF. Data on Polish experience with nintedanib in IPF are lacking. The present study aimed to describe the safety and efficacy profiles of nintedanib in a large real-world cohort of Polish patients with IPF. This was a multicenter...

Descripción completa

Detalles Bibliográficos
Autores principales: Majewski, Sebastian, Białas, Adam J., Barczyk, Adam, Batura-Gabryel, Halina, Buchczyk, Małgorzata, Doboszyńska, Anna, Górska, Katarzyna, Grabowska-Skudlarz, Luiza, Jagielska-Len, Hanna, Jarzemska, Agnieszka, Jassem, Ewa, Jastrzębski, Dariusz, Kania, Aleksander, Koprowski, Marek, Krawczyk, Michał, Krenke, Rafał, Lewandowska, Katarzyna, Mackiewicz, Barbara, Martusewicz-Boros, Magdalena M., Milanowski, Janusz, Noceń-Piskorowska, Małgorzata, Nowicka, Agata, Roszkowski-Śliż, Kazimierz, Siemińska, Alicja, Sładek, Krzysztof, Sobiecka, Małgorzata, Stachura, Tomasz, Tomczak, Małgorzata, Tomkowski, Witold, Trzaska-Sobczak, Marzena, Ziora, Dariusz, Żołnowska, Beata, Piotrowski, Wojciech J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10381008/
https://www.ncbi.nlm.nih.gov/pubmed/37510750
http://dx.doi.org/10.3390/jcm12144635

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10381008/
https://www.ncbi.nlm.nih.gov/pubmed/37510750
http://dx.doi.org/10.3390/jcm12144635

Ejemplares similares